Showing results (81-90 of 1,984) with videos related to
Sort By:
Pageof 199
The Annals of Applied Statistics|November 5, 2019
Bayesian Semiparametric Joint Regression Analysis of Recurrent Adverse Events and Survival in Esophageal Cancer PatientsJuhee Lee, Peter F Thall, Steven H LinJournal of Clinical Anesthesia|August 24, 2024
Intraoperative methadone administration for total mastectomy: A single center retrospective studyJuan P Cata, Yusuf Zaidi, Juan Jose Guerra-Londono, et al.Blood Advances|November 10, 2020
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsBetül Oran, Marcos de Lima, Guillermo Garcia-Manero, et al.Journal of the Royal Statistical Society. Series C, Applied Statistics|April 2, 2016
Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free SurvivalBrian P Hobbs, Peter F Thall, Steven H LinJournal of the Royal Statistical Society. Series C, Applied Statistics|March 4, 2017
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal OutcomesPeter F Thall, Hoang Q Nguyen, Ralph G ZinnerPharmaceutical Statistics|July 6, 2017
Bayesian nonparametric statistics: A new toolkit for discovery in cancer researchPeter F Thall, Peter Mueller, Yanxun Xu, et al.Journal of the American Statistical Association|September 15, 2015
Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and ToxicityJuhee Lee, Peter F Thall, Yuan Ji, et al.Biostatistics (Oxford, England)|November 11, 2015
A decision-theoretic phase I-II design for ordinal outcomes in two cyclesJuhee Lee, Peter F Thall, Yuan Ji, et al.Clinical Trials (London, England)|January 21, 2006
Monitoring event times in early phase clinical trials: some practical issuesPeter F Thall, Leiko H Wooten, Nizar M TannirJournal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 18, 2011
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastasesPaul Mathew, Sijin Wen, Satoshi Morita, et al.Pageof 199